Skip to main content

Three intellectual disability-associated de novo mutations in MECP2 identified by trio-WES analysis



To date, at least 746 genes have been identified to cause intellectual disability (ID). Among them, mutations in the Methyl CpG binding protein 2 (MECP2) gene are the leading cause of Rett syndrome and associated ID.


Considering the large number of ID-associated genes, we applied trio-based whole-exome sequencing (trio-WES) and in silico analysis for genetic diagnosis of 294 children with ID.


Three de novo heterozygous mutations [NM_004992.3: c.502C > T, p.(Arg168*), c.916C > T, p.(Arg306Cys), and c.879C > G, p.(Ile293Met)] in MECP2 were identified in three unrelated girls. The first two mutations were detected in two patients who were diagnosed as typical Rett syndrome, X-linked ID and psychomotor retardation. The third mutation (c.879C > G), a previously unreported, was found in a 6-year-old girl with ID, microcephaly, severe underweight and psychomotor retardation. Particularly, this extremely rare de novo mutation (DNM) is located in the transcriptional repression domain (TRD) of MECP2, where at least 62 different causal mutations are identified.


We identified three DNMs in MECP2 in a cohort of 294 individuals with ID. The novel c.879C > G mutation, as a likely pathogenic allele, may become a risk factor associated with X-linked ID, microcephaly and psychomotor retardation.

Peer Review reports


Intellectual disability (ID) involves early-onset impairments in general mental abilities [1]: 1) intellectual functioning, including reasoning, problem solving, planning, abstract thinking, judgment, academic and experiential learning; 2) adaptive functioning, including conceptual, social and practical skills. The worldwide prevalence of ID is about 10.37/1000 population [2], with an unbalanced sex ratio of 1.3–1.4 to 1 for male to females [3].

85% of patients with ID could be classified as mild ID. Environmental factors, such as malnutrition during pregnancy, perinatal asphyxia, and neurotoxic compounds exposure, are believed to play an important role in the mild ID [4]. Genetic causes are more frequently observed in affected individuals with severe ID [4]. Chromosomal abnormalities, like Down syndrome (trisomy 21) and DiGeorge syndrome (22q11.2 deletion), are the common causes of genetic ID [4]. Monogenic mutations could collectively explain a large proportion of ID cases as well [5]. At least 746 genes that influence intelligence have been identified [5]. Of note, 141 of them are located on X-chromosome [6], such as FMR1 mutations in Fragile X syndrome and MECP2 mutations in Rett syndrome (RTT) [7,8,9,10].

The etiology in about 50% of ID cases remains unknown [2]. Considering the large number of ID-related genes [5], the importance of genetic factors in ID [4], and genetic heterogeneity of the Rett syndrome spectrum resulting from mutations of multiple causative genes [11], we performed trio-whole-exome sequencing (trio-WES) and bioinformatics analysis to identify potential genetic causes for a cohort of 294 affected individuals with ID [11]. In the present study, we report three MECP2-associated de novo mutations (DNMs), including a previously unreported missense mutation.



294 non-homogeneous children (aged from 2 to 10 years) with intellectual disability and possible accompanying other conditions were recruited since 2010. Subjects with established perinatal diseases or chromosomal aneuploidies were not included.

Trio-WES and bioinformatics analysis

Genomic DNAs were isolated from peripheral venous blood leukocytes. Trio-WES with 60× average sequencing depths (97% coverage) and in silico analysis were performed (Angen Gene Medicine Tech, Beijing, China) as previously described [12,13,14]. All mutations were identified utilizing Genome Analysis Toolkit and filtered to exclude the mutations with MAF > 0.001 in gnomAD ( or Chinese Exome Sequence Database (ChES, 5000 Chinese Han individuals, Angen Gene Medicine Tech, Beijing, China) as well as synonymous mutations that do not involve splicing. Deleterious single-nucleotide mutations were predicted by multiple commonly used algorithms, such as SIFT, PolyPhen-2, MutationTaster, and Proven programs [12,13,14]. Potential inherited mutations and DNMs related to neurodevelopmental disorders were screened using a recently developed program mirTrios [15].


Mutation description

A nonsense [NC_000023.10: g.153296777G > A, NM_004992.3: c.502C > T, p.(Arg168*)] and two missense mutations [NC_000023.10: g.153296363G > A, NM_004992.3: c.916C > T, p.(Arg306Cys); NC_000023.10: g.153296400G > C, NM_004992.3: c.879C > G, p.(Ile293Met)] in exon 4 of MECP2 were identified in case 1, case 2 and case 3 respectively. All of the mutations were de novo heterozygous in the affected individuals. The c.502C > T and c.916C > T were further confirmed by Sanger Sequencing using ABI 3700 Genetic Analyzer (ABI, Foster City, CA, USA) (Fig. 1a and Fig. 2a). The c.879C > G mutation was detected in the 3rd case with high-depth reading (heterozygous, 180x vs 160×) in WES report. Sanger Sequencing was not conducted in this case because her DNA sample was no longer available.

Fig. 1

Family 1 and verification of a de novo nonsense mutation c.502C > T, p.(Arg168*) of MECP2. a The mutation is detected in the proband, but not in the parents, is confirmed by Sanger sequencing. b Pedigree of the family and facial photograph of the proband at 3 years old

Fig. 2

Sanger sequencing of the mutation c.916C > T, p.(Arg360Cys) of MECP2 in case 2. a The mutation is present in the proband, but not in the parents, is confirmed by Sanger sequencing. b Pedigree of the family and facial photograph of the proband at 8 years old

To date, at least 1103 different mutations in MECP2 have been curated in HGMD [16] and RettBASE [8]. Mutation spectrum analysis of the gene revealed that the first two alleles (c.502C > T, rs61748421; c.916C > T, rs28935468) we identified, like many other frequently mutated alleles [7], are located in the Methyl-CpG binding domain (MBD) and transcriptional repression domain (TBD) respectively [9].

The novel DNM [c.879C > G, p.(Ile293Met)] dedected in the third patient is also located in TBD (Fig. 3). Within the TBD domain of 104 amino acids (from residue 219 to 322), 62 different pathogenic mutations have been identified (HGMD). In ClinVar and gnomAD, the c.879C > G allele (rs587783140) is extremely rare, which is detected in east Asian (MAF: 0.0002692) and Latino (MAF: 0.00007129), but not in any other populations. Furthmore, only 1 missense mutation p.(Thr240Ser) with a high MAF is found within the TBD domain (gnomAD), suggesting potentially benign mutations are extremely rare in this domain. Although marked as variant of uncertain significance (VUS) in ClinVar, it is predicted to be deleterious by several commonly used algorithms, such as MutationTaster, Polyphen2 and Proven. According to ACMG criteria [17], the p.(Ile293Met) missense mutation is predicted to be likely pathogenic based on the fact that it is a DNM and located in a critical and well established functional domain, rich in pathogenic variants. No additional DNMs or causal alleles, related to ID or psychomotor retardation in autosomal recessive or X-linked form, were identified from the patient in the trio-WES analysis.

Fig. 3

Three de novo mutations in MECP2 identified in this study are located in MBD and TRD domain of MeCP2 protein. Location of the novel DNM p.(Ile293Met) (I293M) in TRD domain is labeled in red. Multiple vertical lines beneath the blue box represent 62 different mutations in TRD domain (HGMD), which appears to be evenly distributed within the domain composed of 104 amino acids. Both p.(Arg168*) (R168X) and p.(Arg306Cys) (R306C) mutations in the first two patients are hot alleles. MeCP2 domains are predicted by SMART analysis ( AT-hook is a DNA-binding motif. Pink boxes represent low compositional complexity regions

Clinical manifestations of three individuals with MECP2 mutations

The 7-year-old girl (case 1) carrying p.(Arg168*) mutation had an uneventful perinatal period and her head circumference was 33 cm (15th, − 1 SD) at birth. She could smile and babble at 5 months, pincer grasp at 11 months, stand and walk independently between 20 and 21 months, speak “papa” and “mama” at 24 months. At 3 years and 2 months (Fig. 1b), she manifested dyspraxic gait and strephexopodia, meanwhile her purposeful hand skills started to disappear, and the repetitive involuntary hand movements arose. At 3 years and 7 months, Gesell Developmental Schedules indicated her development quotient between 11 and 19 months; auditory brainstem response threshold of Auditory Evoked Potentials (AEP) was 20 dBnHL at left and 40 dBnHL at the right side; no abnormalities were found in her brain MRI, EEG and chromosomal analysis. At 5 years and 3 months, she had bruxism and hyperventilation when awake; her head circumference was 48.5 cm (15th, − 1.5 SD), height was 104 cm (15th) and body weight was 18 kg (50th); Wechsler Intelligence Scale for Children (WISC, full-scale IQ 7) indicated profound ID. She could never crawl, climb stairs or speak phrases more than two words. Her parents were phenotypically normal (Fig. 1b).

Clinic manifestation of the patient demonstrated several features of Rett-like syndrome, such as postnatal deceleration of head growth, hand stereotypy, loss of acquired hand skills, early retardation of language and motor development. Additional conditions, such as growth retardation, breathing disturbance and bruxism when awake, were also observed in this case. Combining the genetic finding of MECP2 pathogenic mutation, the diagnosis of typical RTT was made [10].

The 8-year-old girl (case 2, Fig. 2b), who carries the p.(Arg306Cys) mutation, was healthy at birth. She could smile at 3 months, sit steadily at 6 months, crawl and grasp at 12 months. At 24 months, she developed pincer grasp and independent stand, and responded to her name; her head circumference was 48.2 cm (50-85th). At 30 months, she began to babble, and walked with abnormal gait. At 3 years and 1 month, she was found to avoid eye-contact and interaction with others. Clancy Behavior Scale measurement suggested possible autism. Although she did not have a seizure history, EEG detected multifocal epileptic-like discharges during her sleep. At 7 years and 4 months, she showed stereotypic hand movements; her height was 117 cm (15-50th), body weight was 24 kg (50th). Brain MRI and AEP were normal. She could not run, hop, or climb stairs. She could not speak “papa” or “mama”. Due to lack of compliance, WISC and ADOS were not tested. Her family members were phenotypically normal.

Although this patient had hand stereotypy, her normal head growth did not support the diagnosis of RTT [10]. Considering her overall developmental delay and autistic-like features after 6 months, the diagnosis of X-linked ID, psychomotor retardation and possible Autism Spectrum Disorder (ASD) was made [18]. It is estimated that 16.7–40% of ID patients have ASD, whereas ID is seen in 50–70% of ASD patients [19]. Sometimes ID, ASD, RTT and other neurologic diseases share similar clinical features, which has been a challenge in clinical diagnosis.

The 6.5-year-old girl (case 3), who was found to carry p.(Ile293Met) mutation, demonstrated motor retardation in a few months after birth. Her head circumference of 45 cm (< − 3 SD) and weight of 11.2 kg (< − 3 SD). Anterior fontanelle was closed. No abnormalities were found in examination of her heart and lung. Her walking is slower compared to the kids at similar age, probably due to reduced lower-extremity muscle strength (4/5 grade). However, examinations of bilateral knee and ankle tendon reflexes, bilateral Babinski sign, and bilateral ankle clonus were normal. At 3-year-old, her Psychomotor Development Index (PDI) score in Bayley Scales test was only 50 (< 69 for developmental delay), while her Mental Development Index (MDI) score was 70 (< 70 for developmental delay). Her sleep EEG was abnormal, showing few sharp waves and sharp slow waves on both front sides of brain. But no seizure history was documented. Cranial MRI showed abnormal signals in white matter. She was diagnosed as psychomotor retardation, ID, microcephaly and severe underweight. No further clinical information was available because she was lost to follow-up. Her parents were phenotypically normal.


MeCP2 protein is abundantly expressed in brain tissues [9], and selectively binds to DNA sequences with methylated CpG dinucleotides, interacting with histone deacetylases and the transcriptional co-repressors [7, 9]. Extensive target genes have been discovered in recent studies, suggesting that MeCP2 is a genome wide epigenetic modulator [9]. Accordingly, MECP2 mutations have been demonstrated to cause various clinical conditions (HGMD), such as Rett syndrome (678 different mutations), MECP2 duplication syndrome (85), X-linked ID (52), neurodevelopmental delay (35), brain abnormalities (26), atypical Rett syndrome (22), and psychomotor developmental delay (14). It has been observed that a majority of patients with MECP2-caused RTT are sporadic [7, 20] because most pathogenic mutations in MECP2 are de novo mutations [21]. In many cases, DNMs are likely derived from the X chromosome in male sperms [22, 23].

In terms of genotype-phenotype correlations, previous studies showed that females carrying p.Arg168* in MBD domain could manifest more severe symptoms compared to p.(Arg306Cys) [7] in TRD domain (Fig. 3). However, case 2 with p.(Arg306Cys) in our study showed more severe language impairment and extra autistic features compared to case 1 with p.(Arg168*). As shown in Fig. 3, the novel DNM p.(Ile293Met) in case 3 is also located in the TRD domain. Notably, a total of 62 different mutations (HGMD) have been found in this domain that is composed of only 104 amino acids, suggesting its important function to regulate the methylated CpG sites on the DNA strands involved in brain development. Therefore, it is likely that this allele, as a DNM present in the affected case 3, may play a role in the pathogenesis of the her clinic conditions.

Wide phenotypic variations in our cases could be also observed in many other individuals with the same MECP2 mutations. Part of the reasons may be attributed to the existence of many other factors, such as X chromosome inactivation, somatic mosaicism and genetic background [7, 9, 24]. Further genomic sequencing and in-depth bioinformatic analysis may identify more risk mutations in affected individuals with broader neurodevelopmental diseases, which may allow a better deciphering of the pathophysiology of neurodevelopmental disorders.


Three DNMs in the MECP2 gene, including the previously unreported missense mutation p.(Ile293Met), are identified by trio-WES analysis from 294 children with ID. Our findings may expand the MECP2-associated mutational and phenotypic spectrum in affected individuals with ID and other accompanying conditions.

Availability of data and materials

The datasets generated and analysed during the current study are available [doi:] in the Mendeley Data repository ( No additional supporting files are available for further studies.



Methyl CpG binding protein 2


Intellectual disability


Whole-exome sequencing


de novo mutation


Rett syndrome


Deoxyribonucleic acid


Minor allele frequency


Human Gene Mutation Database


Methyl-CpG binding domain


Transcriptional repression domain


Variant of uncertain significance


The American College of Medical Genetics and Genomics


standard deviation


Autism Diagnostic Observation Schedule


Auditory Evoked Potentials


Magnetic resonance imaging




Wechsler Intelligence Scale for Children


Intelligence quotient


Autism spectrum disorder


Psychomotor Development Index


Mental Development Index


  1. 1.

    First MB. Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis. 2013;201(9):727–9.

    Article  Google Scholar 

  2. 2.

    Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32(2):419–36.

    Article  Google Scholar 

  3. 3.

    Lubs HA, Stevenson RE, Schwartz CE. Fragile X and X-linked intellectual disability: four decades of discovery. Am J Hum Genet. 2012;90(4):579–90.

    CAS  Article  Google Scholar 

  4. 4.

    van Bokhoven H. Genetic and epigenetic networks in intellectual disabilities. Annu Rev Genet. 2011;45:81–104.

    Article  Google Scholar 

  5. 5.

    Kochinke K, Zweier C, Nijhof B, Fenckova M, Cizek P, Honti F, Keerthikumar S, Oortveld MA, Kleefstra T, Kramer JM, et al. Systematic Phenomics analysis Deconvolutes genes mutated in intellectual disability into biologically coherent modules. Am J Hum Genet. 2016;98(1):149–64.

    CAS  Article  Google Scholar 

  6. 6.

    Neri G, Schwartz CE, Lubs HA, Stevenson RE. X-linked intellectual disability update 2017. Am J Med Genet A. 2018;176(6):1375–88.

    Article  Google Scholar 

  7. 7.

    Cuddapah VA, Pillai RB, Shekar KV, Lane JB, Motil KJ, Skinner SA, Tarquinio DC, Glaze DG, McGwin G, Kaufmann WE, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet. 2014;51(3):152–8.

    CAS  Article  Google Scholar 

  8. 8.

    Krishnaraj R, Ho G, Christodoulou J. RettBASE: Rett syndrome database update. Hum Mutat. 2017;38(8):922–31.

    Article  Google Scholar 

  9. 9.

    Liyanage VR, Rastegar M. Rett syndrome and MeCP2. NeuroMolecular Med. 2014;16(2):231–64.

    CAS  Article  Google Scholar 

  10. 10.

    Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, Leonard H, Bailey ME, Schanen NC, Zappella M, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944–50.

    Article  Google Scholar 

  11. 11.

    Vidal S, Xiol C, Pascual-Alonso A, O'Callaghan M, Pineda M, Armstrong J. Genetic Landscape of Rett Syndrome Spectrum: Improvements and Challenges. Int J Mol Sci. 2019;20(16):3925.

  12. 12.

    Guo S, Yang L, Liu H, Chen W, Li J, Yu P, Sun ZS, Chen X, Du J, Cai T. Identification of novel compound mutations in PLA2G6-associated Neurodegeneration patient with characteristic MRI imaging. Mol Neurobiol. 2017;54(6):4636–43.

    CAS  Article  Google Scholar 

  13. 13.

    Ma D, Wang X, Guo J, Zhang J, Cai T. Identification of a novel mutation of RUNX2 in a family with supernumerary teeth and craniofacial dysplasia by whole-exome sequencing: a case report and literature review. Medicine (Baltimore). 2018;97(32):e11328.

    CAS  Article  Google Scholar 

  14. 14.

    Yu P, Cui Y, Cai W, Wu H, Xiao X, Shao Q, Ma L, Guo S, Wu N, Jin ZB, et al. Lysosomal storage disease in the brain: mutations of the beta-mannosidase gene identified in autosomal dominant nystagmus. Genet Med. 2015;17(12):971–9.

    CAS  Article  Google Scholar 

  15. 15.

    Li J, Jiang Y, Wang T, Chen H, Xie Q, Shao Q, Ran X, Xia K, Sun ZS. Wu J: mirTrios: an integrated pipeline for detection of de novo and rare inherited mutations from trios-based next-generation sequencing. J Med Genet. 2015;52(4):275–81.

    CAS  Article  Google Scholar 

  16. 16.

    Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN. Human gene mutation database (HGMD): 2003 update. Hum Mutat. 2003;21(6):577–81.

    CAS  Article  Google Scholar 

  17. 17.

    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.

    Article  Google Scholar 

  18. 18.

    Gnanavel S, Robert RS. Diagnostic and statistical manual of mental disorders, fifth edition, and the impact of events scale-revised. Chest. 2013;144(6):1974.

    Article  Google Scholar 

  19. 19.

    Matson JL, Shoemaker M. Intellectual disability and its relationship to autism spectrum disorders. Res Dev Disabil. 2009;30(6):1107–14.

    Article  Google Scholar 

  20. 20.

    Zhang Q, Zhao Y, Bao X, Luo J, Zhang X, Li J, Wei L, Wu X. Familial cases and male cases with MECP2 mutations. Am J Med Genet B Neuropsychiatr Genet. 2017;174(4):451–7.

    CAS  Article  Google Scholar 

  21. 21.

    Genetica Medica. Accessed by 01/06/2019.

  22. 22.

    Zhang X, Bao X, Zhang J, Zhao Y, Cao G, Pan H, Zhang J, Wei L, Wu X. Molecular characteristics of Chinese patients with Rett syndrome. Eur J Med Genet. 2012;55(12):677–81.

    Article  Google Scholar 

  23. 23.

    Thomas GH. High male:female ratio of germ-line mutations: an alternative explanation for postulated gestational lethality in males in X-linked dominant disorders. Am J Hum Genet. 1996;58(6):1364–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Hoffbuhr KC, Moses LM, Jerdonek MA, Naidu S, Hoffman EP. Associations between MeCP2 mutations, X-chromosome inactivation, and phenotype. Ment Retard Dev Disabil Res Rev. 2002;8(2):99–105.

    CAS  Article  Google Scholar 

Download references


The authors are grateful to all the family members for their participation.


This study was supported by the research funding from the Chinese Ministry of Health Project (No: 201302002 to XC). This research was supported in part by the Intramural Research Program of NIDCR/NIH. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information




TC, BX and XC designed the study. LZ, XM performed laboratory experiments and data analysis. BX and XC collected the clinical data and interpreted the data. TC reviewed and verified the data. YG drafted the manuscript. YG and TC revised the manuscript critically for intellectual content. All authors gave intellectual input to the study and approved the final version of the manuscript.

Corresponding author

Correspondence to Tao Cai.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the ethics committee of the Wenzhou Medical University, the Second Affiliated Hospital (LCKY2019–200), and written informed consents for participation of this study were obtained from the probands’ parents.

Consent for publication

Written informed consents for publication of these cases were obtained from the patients’ parents.

Competing interests

The authors declare that they have no competing interests. The author Tao Cai is a member of the editorial board for the BMC Medical Genetics journal.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gu, Y., Xiang, B., Zhu, L. et al. Three intellectual disability-associated de novo mutations in MECP2 identified by trio-WES analysis. BMC Med Genet 21, 99 (2020).

Download citation


  • MECP2
  • Intellectual disability (ID)
  • Rett syndrome
  • Whole-exome sequencing (WES)
  • de novo mutation (DNM)